Chapter review

Fitzgerald PMHNP board review. ch08. Mood Disorders. This is drive 1 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Depressive disorders: criteria, specifiers, timelines, and differentials. Topic. MDD Diagnostic Criteria. MDD Diagnostic Criteria. Bottom Line Summary. - **Diagnostic Timeline and Threshold**: Diagnosis requires 5 or more of 9 symptoms present nearly every day during the same 2-week period, representing a distinct change from previous functioning. - **Core Symptom Requirement**: At least 1 of the 5 required symptoms must be either **depressed mood** or **anhedonia** (loss of interest or pleasure). - **Key Mnemonic**: The **SIG E CAPS** mnemonic summarizes the 9 diagnostic criteria: **Sleep** changes, **Interest** loss, **Guilt** or worthlessness, **Energy** loss, **Concentration** impairment, **Appetite** or weight changes, **Psychomotor** retardation or agitation, and **Suicidal** ideation. - **Epidemiology Metrics**: Lifetime prevalence is 12 percent, with a 2 to 1 female-to-male ratio. Prevalence in young adults aged 18 to 29 is 3 times higher than in adults over 60, with a mean onset between 20 and 35 years. - **Heritability and Inpatient Risk**: Heritability is 40 percent with a 2 to 4 times higher risk in first-degree relatives. Medical inpatients carry a 15 percent higher risk of **major depressive disorder** than the general population. - **Prognosis and Bipolar Conversion**: Untreated episodes last 6 to 13 months, and 50 percent of hospitalized patients recover within 1 year. Crucially, 5 to 10 percent of patients initially diagnosed with **major depressive disorder** develop a manic episode 6 to 10 years later. - **PHQ-9 Severity Ranges**: Scores of 0 to 4 indicate minimal depression, 5 to 9 indicate **mild depression**, 10 to 14 indicate **moderate depression**, 15 to 19 indicate **moderately severe depression**, and 20 to 27 indicate **severe depression**. - **Functional Measurement**: The self-administered **WHODAS** evaluates disability across 6 functional domains and replaced the subjective clinician-assessed Global Assessment of Functioning score. Diagnostic Criteria and Clinical Features. A diagnosis of **major depressive disorder** requires a cluster of observable signs and internal symptoms that disrupt interpersonal, social, or occupational functioning. An isolated complaint of low mood is insufficient for diagnosis. Core Symptom Logic and Screening. - The initial evaluation relies on screening for **depressed mood** and **anhedonia**. - Using the **PHQ-2** screening tool, if a patient denies both depressed mood and loss of interest or pleasure, **major depressive disorder** is ruled out. - A patient can deny feeling sad, down, or blue, but if **anhedonia** is present along with 4 other qualifying criteria, the full diagnostic threshold for a major depressive episode is satisfied. SIG E CAPS Criteria Breakdown. - **Sleep**: Insomnia or hypersomnia where sleep fails to feel restorative. - **Interest**: **Depressed mood** or **anhedonia**. Mood often shows a marked diurnal variation, presenting worst in the morning and improving as the day progresses. In children and adolescents, **irritability** serves as a diagnostic depression equivalent. - **Guilt**: Feelings of worthlessness or excessive, inappropriate, and potentially delusional guilt. - **Energy**: Severe fatigue, lack of ambition, or feeling physically drained. - **Concentration**: Diminished ability to think clearly, indecisiveness, or memory complaints that can mimic **pseudodementia** in older adults. - **Appetite**: Significant weight loss or weight gain, loss of food enjoyment, or failure to achieve expected weight gain in pediatric patients. - **Psychomotor**: Observable **psychomotor retardation** described as walking through quicksand, or **psychomotor agitation** marked by inner restlessness. - **Suicide**: Recurrent thoughts of death, passive **suicidal ideation** without a plan, or active suicide attempts. Clinical Signposts. - **First-line**: Screen every patient presenting with depressive symptoms for a past history of mania or hypomania to rule out **bipolar disorder** before starting treatment. - **Safety alert**: Continuously assess for **suicidal ideation** and active plans. Passive thoughts of death are most common, but active intent requires immediate safety planning and potential inpatient admission. - **Board trap**: Bereavement is not an automatic exclusion for a major depressive episode, nor is altered mood from bereavement a diagnostic criterion itself. Clinical judgment is required to distinguish normal grief from a major depressive episode. Epidemiology and Clinical Course. - **Prevalence**: Lifetime prevalence is 12 percent. Women are affected at twice the rate of men. - **Age Dynamics**: Prevalence in adults aged 18 to 29 is 3 times higher than in adults over age 60. The mean age of onset is between 20 and 35 years. - **Medical Comorbidity**: Medical inpatients have a 15 percent higher prevalence of **major depressive disorder** than the general population. Common psychiatric comorbidities include **ADHD**, **anxiety disorders**, **PTSD**, conduct disorder, learning disabilities, and **substance use disorders**. - **Genetics**: Heritability is estimated at 40 percent. First-degree relatives face a 2 to 4 times higher risk than the general population. - **Prognosis**: Untreated episodes last 6 to 13 months. Following hospitalization, 50 percent of patients recover within 1 year. Between 5 and 10 percent of patients with **major depressive disorder** will experience a manic episode 6 to 10 years after their initial depressive event. Rating Scales and Disability Metrics. - **PHQ-9**: Scores of 1 to 4 reflect minimal depression, 5 to 9 reflect **mild depression**, 10 to 14 reflect **moderate depression**, 15 to 19 reflect **moderately severe depression**, and 20 to 27 reflect **severe depression**. - **WHODAS**: The World Health Organization Disability Assessment Schedule is a self-administered tool measuring functional disability across cognition, mobility, self-care, getting along with people, life activities, and participation in society. It replaces the obsolete Global Assessment of Functioning score. Differential Diagnosis. - **Medical and Substance Rule-Outs**: Always rule out direct physical causes such as hypothyroidism, cerebrovascular accidents, or Parkinson's disease, as well as substance-induced mood changes from alcohol, stimulants, or prescribed medications like steroids. - **Bipolar Spectrum**: Differentiate unipolar depression from **bipolar I disorder**, **bipolar II disorder**, and **cyclothymic disorder**. - **Other Depressive Conditions**: Consider **persistent depressive disorder** (dysthymia, requiring depressed mood plus 2 symptoms for at least 2 years in adults or 1 year in children without symptom-free periods exceeding 2 months), **adjustment disorder with depressed mood** (symptoms within 3 months of an identifiable stressor not meeting full MDD criteria), **premenstrual dysphoric disorder** (luteal phase symptoms remitting around menses), and **schizoaffective disorder**. Sample Test Questions. Question 1. Which of the following statements is false regarding the diagnosis of major depression? - A. More likely to occur in men than women - B. Higher prevalence for whites than blacks - C. Lifetime prevalence is 12% - D. Risk factors include genetics and low education Pause. Answer. A. - **Why It Is Correct**: **Major depressive disorder** is twice as common in women as in men (2 to 1 female-to-male ratio). Therefore, statement A is false. - **Why the Other Choices Are Wrong**: - A. Correct choice because the statement is false. - B. Incorrect because epidemiological data show a higher prevalence in whites than in blacks. - C. Incorrect because 12 percent is the established lifetime prevalence. - D. Incorrect because genetic factors and lower education are known risk factors for depression. Question 2. Karen, a 48-year-old married woman with two teenage children who works as an administrative assistant at the local community college, presents for concerns about irritability. You administer a PHQ-9 and she scores a 17. You assess that she has: - A. Mild depression - B. Moderately severe depression - C. Severe depression - D. No evidence of depression Pause. Answer. B. - **Why It Is Correct**: A **PHQ-9** score of 17 falls directly into the **moderately severe depression** range of 15 to 19. - **Why the Other Choices Are Wrong**: - A. Incorrect because **mild depression** corresponds to a **PHQ-9** score of 5 to 9. - B. Correct choice based on standardized score ranges. - C. Incorrect because **severe depression** corresponds to a score of 20 to 27. - D. Incorrect because a score of 0 to 4 represents minimal or no depression. Question 3. Which of the following is not a DSM-5-TR criterion for major depressive episode? - A. Hypersomnia - B. Loss of food enjoyment - C. Fatigue - D. Altered mood associated with bereavement Pause. Answer. D. - **Why It Is Correct**: Altered mood associated with bereavement is not a diagnostic criterion for a major depressive episode in the DSM-5-TR. - **Why the Other Choices Are Wrong**: - A. Incorrect because hypersomnia is a qualifying criterion under sleep disturbances. - B. Incorrect because loss of food enjoyment is a qualifying criterion under appetite alterations. - C. Incorrect because fatigue is a qualifying criterion under energy reduction. - D. Correct choice as bereavement mood alteration is excluded from the diagnostic criterion list. 📌 Next best study step: Would you like to cover the next leaf in this branch, **Classification of Depressive Disorders**, or focus on active recall flashcard drills for **SIG E CAPS** and **PHQ-9** score thresholds? Next. Topic. Mnemonic: SIG E CAPS. Bottom Line. * **Major depressive disorder** diagnosis requires at least 5 of 9 criteria present nearly every day during a minimum **2-week** timeline, with at least 1 core criterion being **depressed mood** or **anhedonia**. * The lifetime prevalence of **major depressive disorder** is 12%, with a 2-fold higher risk in women compared to men, and a 3-times higher prevalence in adults aged 18 to 29 compared to those over 60. * **First-line** screening utilizes the **PHQ-2** (evaluating **depressed mood** and **anhedonia**) followed by the **PHQ-9**, where severity is scored as 5 to 9 for **mild**, 10 to 14 for **moderate**, 15 to 19 for **moderately severe**, and 20 to 27 for **severe** depression. * The **SIG E CAPS** mnemonic memory hook links the Latin prescription direction "sig" with "energy capsules" to systematically recall all 8 symptom domains. * Medical inpatients carry a 15% higher risk of **major depressive disorder** than the general population, and first-degree relatives have a 2-to-4 times higher genetic risk with a 40% heritability rate. * **Safety alert**: Screening for prior manic or hypomanic episodes is mandatory before confirming unipolar **major depressive disorder** or initiating psychotropics, as 5% to 10% of patients diagnosed with depression experience a manic episode 6 to 10 years later. * **Board trap**: Assuming a patient cannot have **major depressive disorder** if they deny feeling sad or blue is a common error; meeting criteria through **anhedonia** plus 4 other symptoms satisfies the diagnosis. Clinical Teaching: Mnemonic SIG E CAPS and Depressive Criteria. Mnemonic Origin and Diagnostic Framework. The **SIG E CAPS** mnemonic serves as a structured clinical tool to evaluate the diagnostic criteria for a major depressive episode. The word sig originates from the Latin prescription instruction for directions, while E CAPS represents energy capsules. This mnemonic reminds the provider to prescribe energy capsules by systematically reviewing the nine core DSM-5-TR symptom domains. To meet criteria for **major depressive disorder**, a patient must demonstrate at least 5 of the 8 SIG E CAPS domains nearly every day during the same **2-week** period. This presentation must represent a distinct change from previous functioning and cause significant impairment in social, occupational, or interpersonal roles. Crucially, at least 1 of the required 5 symptoms must be either **depressed mood** or **anhedonia**. In children and adolescents, **irritable mood** serves as an official diagnostic equivalent for depressed mood. Breakdown of the SIG E CAPS Symptom Domains. * **S** - **Sleep**: Disturbance presenting as insomnia (difficulty falling asleep, middle awakening, or early morning awakening) or non-restful hypersomnia where the patient sleeps excessively but wakes unrefreshed. * **I** - **Interest**: **Anhedonia**, defined as a marked loss of interest or pleasure in almost all daily activities. This domain also encompasses **depressed mood**, which often exhibits a distinct diurnal variation where patients feel most severe depression upon waking in the morning with slight improvement as the day progresses. * **G** - **Guilt**: Pathologic feelings of worthlessness, self-reproach, or excessive and inappropriate guilt that may reach near-delusional or frank delusional proportions. * **E** - **Energy**: Chronic fatigue, loss of energy, or a total lack of ambition to complete routine tasks. * **C** - **Concentration**: Diminished ability to think, concentrate, or make simple decisions. Patients frequently report inability to finish reading a single page and may express fear that they are developing **dementia** or organic cognitive decline. * **A** - **Appetite**: Unintended weight loss or weight gain, or significant decrease or increase in appetite. It also includes loss of food enjoyment. In pediatric patients, this criterion includes failure to achieve expected developmental weight gains. * **P** - **Psychomotor**: **Psychomotor retardation** or **psychomotor agitation** that is observable by others, not merely subjective feelings. Patients often describe retardation as feeling as though they are walking through quicksand, while agitation presents as pacing or feeling restless inside their own skin. * **S** - **Suicide**: Recurrent thoughts of death, passive suicidal ideation without a plan (the most common presentation), active suicidal ideation with a plan or intent, or a definitive suicide attempt. Diagnostic Timelines and Differential Signposts. * **First-line** assessment: Administer the **PHQ-2** screening tool. Because **depressed mood** or **anhedonia** must be present to establish the diagnosis, a negative **PHQ-2** effectively rules out a major depressive episode. If positive, proceed immediately to the **PHQ-9**. * **Board trap**: Confusing bereavement with a major depressive episode. Uncomplicated grief fluctuates in waves tied to thoughts of the deceased, whereas **major depressive disorder** involves persistent unremitting depressed mood and pervasive self-loathing. Bereavement alone is not a DSM-5-TR criterion for **major depressive disorder**. * **Safety alert**: Always rule out **bipolar disorder**, substance-induced mood disruption, and general medical conditions (such as **hypothyroidism** or cerebrovascular accidents) before confirming unipolar **major depressive disorder**. Initiating antidepressant monotherapy in unrecognized **bipolar disorder** can precipitate acute **mania**. Sample Board Practice Questions. Question 1. Which of the following statements is false regarding the diagnosis of major depression? A. More likely to occur in men than women B. Higher prevalence for whites than blacks C. Lifetime prevalence is 12% D. Risk factors include genetics and low education Pause. Answer. A. **Why It Is Correct:** **Major depressive disorder** is twice as common in women as in men, making option A the false statement. The lifetime prevalence of **major depressive disorder** is 12%, and risk factors include genetic heritability (40%) and lower educational attainment. **Why the Other Choices Are Wrong:** * A. **Major depressive disorder** occurs at twice the rate in females compared to males, making this statement false and therefore the correct answer to the question. * B. Source evidence demonstrates a higher documented prevalence among white individuals compared to Black individuals, making this a true statement. * C. The lifetime prevalence of **major depressive disorder** in the general population is established at 12%, making this a true statement. * D. Established risk factors for **major depressive disorder** include genetic predisposition (2 to 4 times increased risk in first-degree relatives) and lower educational level, making this a true statement. Question 2. Karen, a 48-year-old married woman with two teenage children who works as an administrative assistant at the local community college, presents for concerns about irritability. You administer a PHQ-9 and she scores a 17. With this score, you assess that she has: A. Mild depression B. Moderately severe depression C. Severe depression D. No evidence of depression Pause. Answer. B. **Why It Is Correct:** The **PHQ-9** rating scale categorizes depression severity based on standardized cutoff scores: 5 to 9 indicates **mild depression**, 10 to 14 indicates **moderate depression**, 15 to 19 indicates **moderately severe depression**, and 20 to 27 indicates **severe depression**. A score of 17 falls directly into the **moderately severe depression** range. **Why the Other Choices Are Wrong:** * A. **Mild depression** corresponds to a **PHQ-9** score range of 5 to 9. * B. A score of 17 falls precisely within the 15 to 19 range designating **moderately severe depression**. * C. **Severe depression** requires a **PHQ-9** score of 20 or higher (up to 27). * D. Scores of 0 to 4 indicate minimal or no depression, whereas a score of 17 reflects significant depressive burden. Question 3. Which of the following is not a DSM-5-TR criterion for major depressive episode? A. Hypersomnia B. Loss of food enjoyment C. Fatigue D. Altered mood associated with bereavement Pause. Answer. D. **Why It Is Correct:** Altered mood associated with bereavement is not a distinct diagnostic criterion for a major depressive episode in the DSM-5-TR. While bereavement can trigger a depressive episode in vulnerable individuals, normal grief itself is not listed as a SIG E CAPS criterion. **Why the Other Choices Are Wrong:** * A. Hypersomnia is an official DSM-5-TR criterion representing the **Sleep** domain in the **SIG E CAPS** mnemonic. * B. Loss of food enjoyment and weight or appetite changes represent the official **Appetite** domain in the **SIG E CAPS** mnemonic. * C. Fatigue represents the official **Energy** domain in the **SIG E CAPS** mnemonic. * D. Mood alteration due to bereavement is a clinical context rather than a DSM-5-TR criterion for a major depressive episode. Next. Topic. Table 8-1: MDD Epidemiology and Risk. Bottom Line Summary. * **Lifetime prevalence**: **Major depressive disorder** carries a lifetime prevalence of 12%, making it one of the most frequently tested psychiatric conditions on national board certification exams source 1. * **Gender risk**: Women face a 2 times higher risk for **major depressive disorder** than men (a 2 to 1 female to male ratio), whereas **bipolar I disorder** affects men and women equally [1, 2]. * **Age distribution**: **Major depressive disorder** is primarily a younger person's illness with a mean age of onset between 20 and 35 years [1, 3]. Prevalence in young adults aged 18 to 29 is 3 times higher than in adults over 60 years of age source 1. * **Medical inpatient risk**: Medical inpatients experience a 15% higher risk of **major depressive disorder** than the general population, highlighting the critical role of screening in consultation-liaison settings source 4. * **Heritability and genetics**: **Major depressive disorder** has a heritability of approximately 40% source 5. First-degree relatives of affected individuals have a 2 to 4 times higher risk of developing the disorder compared to the general population source 5. * **High-yield comorbidities**: **Major depressive disorder** frequently co-occurs with non-mood conditions including **ADHD**, **PTSD**, anxiety disorders, conduct disorder, learning disabilities, and **substance use disorders** source 6. * **Demographics**: Reported prevalence of **major depressive disorder** is higher in White populations than Black populations, and lower educational attainment is an established demographic risk factor [7, 8]. High-Yield Concept Map: MDD Epidemiology and Risk. Prevalence and Demographic Risk. When analyzing **major depressive disorder** for board exams, focus on the distinct contrast points between unipolar depression and bipolar spectrum conditions [1, 2]. **Major depressive disorder** has a lifetime prevalence of 12% source 1. Women are twice as likely as men to develop unipolar depression source 1. In contrast, **bipolar I disorder** shows equal prevalence between men and women (1.5% lifetime prevalence), while **bipolar II disorder** (1.2% lifetime prevalence) is more common in women source 2. Age dynamics demonstrate that **major depressive disorder** is predominantly an illness of younger adults source 3. The mean age of onset is between 20 and 35 years, and prevalence declines as age increases [1, 3]. Young adults between 18 and 29 years of age demonstrate a prevalence 3 times higher than adults older than 60 source 1. Bipolar spectrum disorders show an even earlier mean onset between 21 and 24 years source 3. Demographic findings from Fitzgerald highlight that **major depressive disorder** shows a higher reported prevalence in White populations than in Black populations source 8. Lower educational level is also recognized as an environmental and demographic risk factor source 8. Biological and Genetic Risk Factors. Genetics contribute significantly to affective illness [4, 5]. In **major depressive disorder**, heritability accounts for roughly 40% of the disease risk source 5. Having a first-degree relative with **major depressive disorder** increases an individual's personal risk by 2 to 4 times over the general population source 5. Genetic burden is higher in **bipolar disorder**, where first-degree relatives carry a 5% to 10% risk and monozygotic twins demonstrate a 40% to 50% concordance rate source 4. Etiology in unipolar depression combines genetic predisposition, early life adversity, ongoing stress, and neurotransmitter dysregulation in key neural circuits [9, 10]. Clinical Settings, Comorbidities, and Signposts. **Safety alert**: Medical inpatients carry a 15% higher risk of **major depressive disorder** than the general population source 4. On inpatient consultation-liaison units, always evaluate medical inpatients presenting with apathy, fatigue, or low mood for active suicidal ideation and rule out organic medical causes before assuming symptoms are merely expected grief or physical illness [4, 11]. **Board trap**: Exam items frequently present patients with non-mood primary conditions and ask if depression screening is necessary. **Major depressive disorder** has high comorbidity with non-mood psychiatric conditions such as **ADHD**, **PTSD**, anxiety disorders, conduct disorder, learning disabilities, and **substance use disorders** source 6. Never attribute depressive symptoms solely to a co-occurring disorder without formally screening with standardized tools like the **PHQ-9** [6, 12]. **First-line**: The initial step in managing **major depressive disorder** is establishing and maintaining a therapeutic alliance source 13. Diagnostic confirmation requires identifying at least 5 **SIGECAPS** criteria for a minimum duration of 2 weeks, with at least one required cardinal symptom being depressed mood or loss of interest or pleasure (anhedonia) source 14. Fitzgerald Sample Practice Question. Question 1. Which of the following statements is false regarding the diagnosis of major depression? - A. More likely to occur in men than women - B. Higher prevalence for whites than blacks - C. Lifetime prevalence is 12% - D. Risk factors include genetics and low education Pause. Answer. **Keyed Answer**: A source 7 **Why It Is Correct**: Statement A is false because **major depressive disorder** is twice as likely to occur in women as in men (a 2 to 1 female to male ratio) [1, 7]. Because the question specifically asks for the false statement, option A is the correct answer to select source 7. **Why the Other Choices Are Wrong**: - A. Option A is the false statement requested by the stem, as women have double the risk of men for developing **major depressive disorder** [1, 7]. - B. Option B is a true statement based on Fitzgerald board review data, which notes a higher reported prevalence of **major depressive disorder** in White populations compared to Black populations source 8. - C. Option C is a true statement because the established lifetime prevalence for **major depressive disorder** is 12% [1, 8]. - D. Option D is a true statement because genetic heritability (40% heritability and a 2 to 4 times risk increase in first-degree relatives) and lower educational status are documented risk factors for **major depressive disorder** [5, 8]. **Test-Taking Pearl**: When question stems contain negative modifiers like "false" or "except," write down whether each option is True or False next to your answer choices. The single "False" option is your correct answer on board exams source 7. 🎯 **Next Study Step**: Proceed to review **Table 8-2: Major Depressive Disorder Criteria and the SIGECAPS Mnemonic** to master exact diagnostic criteria thresholds, pediatric symptom equivalents, and screening workflows [14, 15]. Next. Topic. Course and Prognosis. Bottom Line Summary. * Untreated major depressive episodes typically last 6 to 13 months, with 50 percent of hospitalized patients recovering within the first year. * A unipolar depression diagnosis carries a 5 to 10 percent risk of converting to Bipolar Disorder, as patients develop a manic episode 6 to 10 years after their initial depressive event. * Recurrence is common: 20 percent of patients experience a relapse within 6 months of remission, and 50 to 85 percent suffer at least one lifetime recurrence. * Continuation phase treatment requires keeping the patient on full therapeutic antidepressant doses for 4 to 9 months post-remission to prevent immediate relapse. * Maintenance phase pharmacotherapy is indicated indefinitely for patients with 3 or more lifetime major depressive episodes or severe co-occurring risk factors. * Discontinuation of antidepressant therapy requires a 6-week gradual taper to avoid withdrawal symptoms, followed by a mandatory clinic evaluation at 2 months post-cessation. * Psychotherapy provides a lower long-term relapse rate than pharmacotherapy alone because it equips patients with structural cognitive and behavioral coping skills. Course and Prognosis Clinical Teaching. Epidemiological Timelines and Course. Major depressive disorder is a chronic and relapsing psychiatric illness. When left untreated, a major depressive episode generally persists for 6 to 13 months. Following inpatient hospitalization for a severe episode, approximately 50 percent of patients achieve recovery within the first 12 months. A critical diagnostic nuance involves longitudinal conversion to bipolar spectrum illness. Between 5 and 10 percent of individuals initially presenting with unipolar major depression will experience a manic or hypomanic episode 6 to 10 years after their index depressive episode, shifting their formal diagnosis to Bipolar I or Bipolar II Disorder. Safety Alert. Unipolar antidepressant monotherapy in a patient with unsuspected bipolar disorder can precipitate acute mania, rapid cycling, or severe behavioral agitation. Always screen for past periods of elevated mood, decreased need for sleep, or racing thoughts before initiating or continuing depression treatment. Recurrence Risk Factors and Longitudinal Dynamics. Recurrence rates in unipolar depression are high. Approximately 20 percent of patients experience a depressive relapse within the first 6 months following symptom remission. Over a lifetime, 50 to 85 percent of individuals who experience a single major depressive episode will suffer at least one subsequent episode. Key clinical risk factors that significantly elevate the likelihood of major depressive disorder recurrence include: * A history of 3 or more prior major depressive episodes. * Persistent residual mild depressive symptoms rather than complete symptom remission. * High severity of past episodes, including past suicidal attempts or psychotic features. * Early age of onset, particularly during adolescence or early adulthood. * Co-occurring non-affective psychiatric disorders, such as generalized anxiety disorder, panic disorder, ADHD, or substance use disorders. * Co-occurring general medical conditions, such as type 1 diabetes mellitus, cerebrovascular accidents, or chronic pain. * A strong family history of mood disorders or psychiatric illness. * Ongoing psychosocial stressors, lack of social support, and persistent sleep disruptions. Board Trap. Do not mistake symptom remission for cure. Stopping an antidepressant immediately upon symptom resolution frequently leads to rapid relapse. Patients must complete a 4 to 9 month continuation phase at full therapeutic dosage before any medication taper is considered. Furthermore, patients with 3 or more lifetime episodes should remain on maintenance therapy indefinitely. Treatment Phases, Discontinuation, and Follow-Up. Management of major depressive disorder is structured across distinct phases: First-line continuation phase therapy requires maintaining the patient on the exact therapeutic dose that induced remission for an additional 4 to 9 months. This brings the total treatment duration for a single episode to approximately 12 months. First-line maintenance phase therapy is indicated for patients with 3 or more lifetime major depressive episodes, or those with 2 episodes plus severe risk factors like medical comorbidities or high suicide risk. In this phase, pharmacotherapy is continued at full therapeutic dosage indefinitely to prevent future recurrences. When discontinuing pharmacotherapy in a stable patient who does not require long-term maintenance: * Never stop medications abruptly. Taper the drug gradually over approximately 6 weeks to prevent antidepressant discontinuation syndrome. * Avoid initiating a taper immediately prior to or during major life stressors, such as starting graduate school, moving, or major holiday periods. * Educate the patient and family on early personal warning signs of relapse, such as subtle changes in sleep patterns, social withdrawal, or missed work. * Schedule a mandatory follow-up evaluation 2 months after complete cessation of medication to assess for early recurrence during the vulnerable post-discontinuation window. Psychotherapy Versus Pharmacotherapy Relapse Protection. While antidepressant medications effectively reduce acute depressive symptoms, psychotherapy (such as Cognitive Behavioral Therapy or Interpersonal Therapy) demonstrates lower relapse rates following treatment discontinuation. Psychotherapy teaches active cognitive restructuring, emotional regulation, and interpersonal problem-solving skills that endure long after active therapy sessions end. Sample Board Practice Questions. Question 1. A 22-year-old male with type 1 diabetes mellitus and generalized anxiety disorder is currently being successfully treated for major depressive disorder, recurrent. He has been symptom-free for the past six months on sertraline 100 mg daily and asks if he can stop taking his medication. You counsel that he has a high risk of recurrence because of which of the following factors? A. Past episodes of depression B. Presence of a chronic medical condition C. Co-occurring anxiety disorder D. All of the above Pause. Answer: D. Why It Is Correct: All listed factors contribute to a significantly elevated risk of major depressive disorder recurrence. The patient possesses multiple high-risk predictors, including a history of recurrent depressive episodes, a chronic medical condition (type 1 diabetes mellitus), a co-occurring psychiatric condition (generalized anxiety disorder), and a young age of onset. Why the Other Choices Are Wrong: * A: While a history of past depressive episodes increases recurrence risk, selecting option A alone ignores the documented impact of his chronic medical illness and co-occurring anxiety. * B: While chronic medical illness elevates recurrence risk, selecting option B alone fails to account for his recurrent psychiatric history and anxiety disorder. * C: While co-occurring anxiety raises recurrence risk, selecting option C alone overlooks his recurrent depression history and medical comorbidity. Question 2. Which of the following statements is FALSE regarding the discontinuation of treatment for stable major depressive disorder? A. Psychotherapy carries a lower risk of relapse after discontinuation than psychopharmacotherapy alone B. Treatment should be discontinued immediately once remission is achieved rather than tapering doses C. Patients and families should be educated on early individual signs and symptoms of relapse D. A follow-up visit should be scheduled two months following the complete cessation of treatment Pause. Answer: B. Why It Is Correct: Statement B is false because psychotropic medications must never be stopped abruptly. Antidepressants should be tapered gradually over approximately 6 weeks to avoid antidepressant discontinuation syndrome and prevent rebound mood instability. Why the Other Choices Are Wrong: * A: Statement A is true because psychotherapy equips patients with long-term cognitive and behavioral skills, resulting in lower post-treatment relapse rates compared to medication alone. * C: Statement C is true because educating patients and families on early warning signs (such as sleep disruption or fatigue) allows for prompt intervention before full relapse occurs. * D: Statement D is true because scheduling a follow-up evaluation 2 months after medication cessation ensures structured monitoring during the initial high-risk post-discontinuation window. Question 3. A 28-year-old man who works as an accountant is being treated with paroxetine 20 mg daily for major depressive disorder. After six weeks of therapy, he reports minimal improvement, and his Zung depression scale score remains elevated at 65. Which of the following clinical strategies would NOT be recommended? A. Increase the dose of paroxetine B. Continue paroxetine and begin evidence-based psychotherapy C. Switch to a therapeutic dose of an SNRI such as venlafaxine D. Discontinue paroxetine and start psychotherapy sessions alone Pause. Answer: D. Why It Is Correct: Discontinuing medication to initiate psychotherapy alone is not recommended for moderate to severe depression (a Zung score of 65 indicates severe depressive symptoms). Guidelines specify that severe depression requires pharmacotherapy or combined medication and psychotherapy; psychotherapy alone is insufficient for severe illness. Why the Other Choices Are Wrong: * A: Increasing the dose of paroxetine is an appropriate strategy to optimize initial monotherapy if the drug was well tolerated. * B: Combining an antidepressant with psychotherapy is an established, highly effective strategy for inadequate treatment response or severe depression. * C: Switching to a different antidepressant class, such as the SNRI venlafaxine, is an evidence-based next step after failing an initial SSRI trial. Next. End of this drive.